Quantcast

Latest Gemtuzumab ozogamicin Stories

2013-12-09 14:01:57

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease....

2013-11-15 23:03:44

St. Jude Children’s Research Hospital leads study showing that a drug withdrawn from the market in 2010 may enhance the effectiveness of bone marrow transplants for select pediatric leukemia patients Memphis, Tenn. (PRWEB) November 15, 2013 Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s...

2013-10-16 23:31:06

MarketResearch.com announces the addition of a new market research report in Biotechnology to their product offering: Antibody Drug Conjugates Market, 2012-2023. http://www.marketresearch.com/land/product.asp?productid=7616267&progid=85808 Rockville, MD (PRWEB) October 16, 2013 Antibody Drug Conjugates Market, 2012-2023 Instead of blasting away at a tumour site, an incision strike is made by locking ADCs onto a target. "This should result in less damage to the body as the...

2012-11-13 10:11:24

A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University. Of the 1,115 patients who took part in the trial, 68 per cent relapsed on the new treatment within three years, compared with 76 per cent of those who had the...

2011-06-06 07:58:03

(Ivanhoe Newswire) -- Researchers have discovered a way of eliminating leukemic stem cells, which could lead to new treatments that may help leukemia patients achieve complete remission. The study showed leukemic stem cells can be abolished by suppressing two proteins found in the bodies of mice. Researchers say leukemic stem cells are responsible for sustaining the disease and are most likely responsible for relapse. Eliminating these cells is believed to be the key for complete remission....

2010-06-21 14:32:00

NEW YORK, June 21 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010. (Logo:...

2010-06-21 14:00:00

SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'